



Little, C. H., Combet, E., McMillan, D. C., Horgan, P. G., and Roxburgh, C. S.D. (2015) The role of dietary polyphenols in the moderation of the inflammatory response in early stage colorectal cancer. *Critical Reviews in Food Science and Nutrition*.

Copyright © 2015 Taylor & Francis

A copy can be downloaded for personal non-commercial research or study, without prior permission or charge

Content must not be changed in any way or reproduced in any format or medium without the formal permission of the copyright holder(s)

<http://eprints.gla.ac.uk/100895/>

Deposited on: 16 June 2015

Enlighten – Research publications by members of the University of Glasgow  
<http://eprints.gla.ac.uk>

# **The Role of Dietary Polyphenols in the Moderation of the Inflammatory Response in Early Stage Colorectal Cancer**

C. H. Little <sup>1</sup>, E Combet <sup>2</sup>, D. C. McMillan <sup>1</sup>, P. G. Horgan <sup>1</sup>, C.S.D. Roxburgh <sup>1</sup>

<sup>1</sup>Academic Unit of Surgery, School of Medicine, University of Glasgow, Royal Infirmary, Glasgow, G4 0SF, UK

<sup>2</sup>Department of Human Nutrition, School of Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Yorkhill Hospital, Glasgow. G3 8SJ, UK

***This is an Accepted Manuscript of an article published by Taylor & Francis in Critical Review in Food Science and Nutrition on June 11<sup>th</sup> 2015 available online: <http://www.tandfonline.com/10.1080/10408398.2014.997866>***

## **Abstract**

Current focus in colorectal cancer management is on reducing overall colorectal cancer mortality by increasing the number of early stage cancers diagnosed and treated with curative intent. There is good evidence that screening for colorectal cancer increases the number of early-stage cancers diagnosed and leads to a reduction of cancer specific mortality. Despite the success of the colorectal cancer screening programme in down-staging colorectal cancer, interval cancer rates are substantial and other strategies to reduce colorectal cancer risk and disease recurrence after surgery with curative intent are desirable.

Sporadic colorectal cancer appears to be largely associated with lifestyle factors including several dietary components, alcohol and tobacco consumption and sedentary lifestyle. Dietary and lifestyle interventions are an attractive option since they are likely to produce other beneficial effects on health. The concept that a diet high in fruit and vegetables lowers the risk of colorectal cancer has been in existence for over 40 years. Polyphenols are phytochemicals that are ingested as part of a normal diet and which are abundant in plant foods including fruits, vegetables and berries. These may, in part, exert their anti-carcinogenic effects via the modulation of inflammatory pathways involved in the initiation and progression of carcinogenesis, since inflammation has recently been recognised as the seventh hallmark of cancer. Therefore, key signal transduction pathways are likely to be fundamental to the association of inflammation and disease progression and the most studied of these in colorectal cancer are those mediated via cyclo-oxygenase, PI3K, NF- $\kappa$ B and STAT.

The aim of the present review was to examine the evidence for the effect of dietary polyphenols intake on both the tumour and host inflammatory responses, in order to determine if polyphenols may be effective as part of a dietary intervention in the context of a

colorectal cancer screening programme. There is now good epidemiological evidence of a reduction in colorectal cancer risk from a number of case-control and cohort studies, which have assessed the relationship between dietary polyphenol intake and colorectal cancer or adenoma formation. Furthermore, there is limited evidence that polyphenols may exert their anti-carcinogenic effects through their anti-inflammatory properties and their effect on signal transduction pathways involving COX, PI3k, NF- $\kappa$ B and STAT. Much of the current research concentrates on isolated flavonoids with no recommendation of dose and therefore it would be premature to suggest a major public health intervention to promote their consumption. However, dietary change is both safe and feasible and this emphasises the need for further investigation of dietary polyphenols and their association with colorectal cancer risk.

## **Keywords**

Colorectal cancer

Colonic polyps

Inflammation

Immune response

Signalling pathways

Lifestyle factors

Polyphenol

Flavonoid

Diet

## Introduction

Colorectal cancer (CRC) is the 2<sup>nd</sup> most common cause of cancer-related death in the UK (2010) accounting for around 10% of all cancer deaths with 41,000 new cases diagnosed per year in the UK and 16,000 deaths (UK CR. Bowel cancer statistics: Cancer Research UK. Available from: <http://info.cancerresearchuk.org/cancerstats/types/bowel/mortality>. Only a small percentage (5-10%) of cases of colorectal cancer arise in patients with known hereditary syndromes (Park et al., 2013) while the majority of cases are sporadic, arising due to multiple alterations and mutations promoting initiation and progression of the dysplasia-cancer sequence (Fearon, 2011b).

One strategy to improve outcomes is to focus on reducing overall colorectal cancer mortality by increasing the number of early stage cancers diagnosed and treated with curative intent, therefore reducing cancer specific mortality. For example, with current standard treatment, reported 5 year survival rates for stages TNM I, II, III and IV disease are 93%, 77%, 48% and 7% respectively. There is good evidence that screening for colorectal cancer increases the number of early-stage cancers diagnosed and the number of precancerous adenomas removed and as a result leads to a reduction of cancer specific mortality (Johnson et al., 2010, Ellul et al., 2010). There was an overall reduction of colorectal cancer mortality of 25% in those who took up testing based on biennial screening (Hewitson et al., 2007).

Despite the success of the colorectal cancer screening programme in down-staging colorectal cancer, interval cancer rates are still substantial accounting for 31.2% of cancers diagnosed in the screened population in the 1<sup>st</sup> round in Scotland, 47.7% in the second round and 58.9% in the third (Steele et al., 2012). With the shift to diagnosis at an earlier stage, a new focus on prevention of recurrence of colorectal cancer is of considerable interest and therefore, other strategies to reduce colorectal cancer risk and disease recurrence after surgery with curative intent are desirable.

Sporadic colorectal cancer appears to be largely associated with lifestyle factors including several dietary components, alcohol and tobacco consumption and sedentary lifestyle (Theodoratou et al., 2014, Park et al., 2012, Chan et al., 2011). The evidence for these associations is convincing, with a 10% decreased risk of CRC per 10g/day increase in intake of dietary fibre, 41% increased risk of CRC for the groups that drank the most alcohol in one large analysis of CRC cases (Cho et al., 2004), 38% increased risk of CRC for an increase of 40 cigarettes/day (Liang et al., 2009) and an 11% decreased risk of CRC and 12% decreased risk of colon cancer per 30 minutes/day of physical activity (WCRF, 2011). Since colorectal cancer develops from a precursor lesion, with approximately 8% of polyps greater than 1cm developing into cancer at 10 years (Stryker et al., 1987), there is the potential advantage that lifestyle interventions may alter the natural history of the disease. Patients with polyps are at an increased risk of developing further polyps and therefore a higher risk of subsequently developing colorectal cancer (Cairns et al., 2010).

Only a few studies investigate the relationship between diet and CRC recurrence; however patients diagnosed with CRC have been shown to be motivated to adjust their dietary and physical activity levels after diagnosis (Patterson et al., 2003, Reedy et al., 2005). Dietary and lifestyle interventions are an attractive option since they are likely to lead to other beneficial effects on health and these may, in part, exert their anti-carcinogenic effects via the modulation of inflammatory pathways involved in the initiation and progression of colorectal carcinogenesis.

The concept that diet may influence colorectal cancer risk is not new; initial observations of the relative rarity of colorectal cancers in African populations that consume a high fibre diet has been published for over 40 years (Burkitt, 1969). Red meat intake has also been implicated as a risk factor for CRC and many epidemiological studies associate an increase in colon cancer or adenoma risk with greater intake of red meat. In the EPIC study,

the absolute risk of developing CRC within 10 years for a 50 year old participant was 1.71% for the highest category of red and processed meat intake and 1.28% for the lowest category (Norat et al., 2005). A recent prospective study of > 500,000 individuals from 10 European populations in the EPIC study showed a 40% reduced risk of CRC with the highest intake of fibre and high fruit and vegetable intake was associated with a modest risk reduction (Bingham et al., 2003). Polyphenols / phenolics have recently attracted attention as potential agents in the modification of inflammation in early stage colorectal cancer and given that inflammation has been identified as the seventh hallmark of cancer, this may be one mechanism by which they may reduce colorectal cancer risk. There is evidence of their effect on inflammation-associated pathways and they have low toxicity profiles compared with current anti-inflammatory medications. Therefore, the aim of the present review was to examine the evidence for the effect of dietary polyphenols on both the tumour and host inflammatory signal transduction pathways in order to determine if polyphenols may be effective as part of a dietary intervention in the context of a colorectal cancer screening programme.

### **Inflammation in colorectal cancer**


Inflammation has recently been recognised as the seventh hallmark of cancer and current evidence suggests a role for inflammation in the pathogenesis (Colotta et al., 2009) and progression of CRC (Hanahan and Weinberg, 2011). In sporadic colorectal cancer, an accumulation of mutations in oncogenes and tumour suppressor genes such as adenomatous polyposis coli (APC) and  $\beta$ -catenin promotes the transition from dysplastic crypt foci to adenoma and subsequent aberrant genetic alterations including loss of p53 function and K-Ras activation encourage progression to colorectal carcinoma (Fearon, 2011a). Inflammation also has a significant role to play in influencing this process (Terzic et al., 2010, Pages et al.,

2010): progression to neoplasia is dependent on growth and pro-survival signals from the tumour microenvironment, secreting factors that recruit inflammatory cells and activate stromal cells.

Ongoing inflammation may be driven by cytokines and chemokines secreted by tumour cells and mast cells, macrophages and B and T cells, which are recruited to the tumour microenvironment. Alterations in cytokine production accompany the development of CRC, polarising from a Th1 type response to a Th2 type response as the tumour progresses along the adenoma-carcinoma sequence (Cui and Florholmen, 2008). Furthermore, there is a strong association between the duration and extent of mucosal inflammation in inflammatory bowel disease and the development of colorectal cancer. In keeping with this concept, the overall risk of colorectal cancer in those with IBD has decreased markedly in the past few decades and this may be a result of improved therapies and better control of colonic inflammation associated with the disease (Jess et al., 2012).

Key components of both local and systemic cancer-related inflammation involve the innate immune response and include tumour necrosis and infiltration with neutrophils and macrophages and pro-inflammatory cytokines such as IL-6, IL-1, TNF- $\alpha$ , EGF and VEGF, which may lead to angiogenesis, cell proliferation and tumorigenesis (Knupfer and Preiss, 2010, Roxburgh and McMillan, 2012). Key signal transduction pathways are likely to be fundamental to the association of inflammation and disease progression in colorectal cancer (Figure 1) and in particular, the activation of cyclo-oxygenase, PI3K, NF- $\kappa$ B and STAT pathways in the tumour cells and their microenvironment (stroma and inflammatory cell infiltrate).





**Figure 1:** The inflammatory response promotes tumour development and progression, and tumour development and progression induces the inflammatory response. Local and systemic inflammatory states and the mediators released enhance metastogenesis. Furthermore, tumour progression and metastasis promotes the local and systemic inflammatory response (Mantovani et al., 2008, Chechlinska et al., 2010). This vicious circle can be interrupted by various agents and there has been recent interest in their administration with the aim of attenuating the inflammatory response associated with carcinogenesis, slowing progression or preventing recurrence and therefore potentially improving survival.

### ***NF-κB***

NF-κB is a family of dimers that are regulators of infection and inflammation and have been identified as a key component of the signal transduction pathways that occur when inflammation progresses to malignancy (Lu et al., 2006). Under normal resting conditions, NF-κB resides in the cytoplasm until it is activated to translocate to the nucleus, where it is involved in the expression of genes which suppress apoptosis, induce cellular transformation, proliferation, invasion, metastasis, chemo- and radio-resistance and inflammation (Aggarwal and Shishodia, 2006). There are multiple factors that are known to activate the NF-κB pathway including inflammatory stimuli, cytokines, viruses and carcinogens. The resulting

activation of target genes such as cyclin D1, apoptosis suppressor proteins (Bcl-2/Bcl-XL), MMP, VEGF and IL-6 may be critical in the development of aggressive cancers (Aggarwal and Shishodia, 2006). NF- $\kappa$ B has effects on both tumour cells and tumour associated inflammatory cells and therefore, NF- $\kappa$ B has become a target in the development of novel strategies to prevent and treat cancer (Sarkar and Li, 2008). It has been shown to be activated to a greater degree in colorectal tumour specimens than in normal tissue and the degree of activation increased with stage of cancer (Kojima et al., 2004).

### *STAT*

Signal transducer and activator of transcription (STAT) proteins are transcription factors. They prevent apoptosis, therefore encouraging cell survival and growth through increased expression of Bcl-2 and Bcl-X (Aggarwal and Shishodia, 2006). STAT3 is activated by many growth factors and cytokines including IL-11, IL-22, EGF, TGF- $\alpha$  or PDGF receptors (Yu et al., 2009). Once activated, STAT3 induces expression of anti-apoptotic genes, proliferative genes such as Cyclin D1 or c-Myc and vascular endothelial growth factor (VEGF) which is responsible for angiogenesis (Terzic et al., 2010). In the tumour cells themselves, STAT3 inhibits apoptosis by up-regulating pro-survival Bcl-2 proteins (Norat et al., 2014, Inoue-Choi et al., 2013). Furthermore, STAT3 induces tumour-associated inflammation by upregulating chemokines capable of attracting immune and inflammatory cells that further enhance STAT3 activity through the production of IL-6, IL-11 and other cytokines (Yu et al., 2009).

In this way, STAT3 has the ability to control and shape the tumour micro-environment. Activation of STAT3 can also lead to prolonged activation of NF- $\kappa$ B, therefore tumour promotion and metastasis (Lee et al., 2009). Studies have suggested that STAT3 activation in

colorectal cancer is increased and this was in a stage specific manner, with more STAT3 identified in the poorly differentiated tumours as well as those of a more progressed T-stage (Baral et al., 2009, Park et al., 2008).

### ***PI3k***

Phosphatidylinositol 3-kinase (PI3K) signalling pathways serve an important role in carcinogenesis (Samuels et al., 2004) regulating cell growth, differentiation, survival, proliferation and migration and mutations in PIK3CA, the gene encoding phosphatidylinositol-4,5-bisphosphonate 3-kinase catalytic subunit alpha polypeptide, are present in 15-20% of colorectal cancers (Barault et al., 2008, Liao et al., 2012, Whitehall et al., 2012). The up-regulation of PI3K enhances prostaglandin-endoperoxide synthase 2 (PTGS2) also known as COX-2, and therefore PGE2 synthesis leading to inhibition of apoptosis in colon-cancer cells (Kaur and Sanyal, 2010). Studies have shown that aspirin may suppress cancer cell growth by blocking the PI3K pathway and inducing apoptosis (Uddin et al., 2010). Furthermore, regular aspirin use after diagnosis of colorectal cancer was associated with longer survival in those patients with mutated PIK3CA colorectal cancer (Kang et al., 2013).

The direct tumoral effects of the PI3K pathway include inhibition of apoptosis, increased cellular proliferation and growth and a reduction in cell-cycle arrest (Le and Fodde, 2008). The PI3K pathway is involved in the function of leukocytes and endothelial cells and they appear to be crucial mediators of inflammatory reactions (Le and Fodde, 2008). As a vital signalling pathway in the innate immune response, PI3K is involved in chemotaxis of neutrophils and macrophages to the site of inflammation (Morrison et al., 2012) and this may be another mechanism by which it is involved in carcinogenesis.

### *Cyclo-oxygenase*

Cyclo-oxygenase-2 (COX2) is an inducible mediator of prostaglandin synthesis and the pro-neoplastic effects of COX2 are mediated by the prostanoid PGE2, its major end product. COX2 has been shown to be over-expressed in colorectal cancers (Sheehan et al., 1999, Dimberg et al., 1999) as has PGE2 (Taketo, 1998, Kawamori et al., 2003) and its expression is associated with tumour invasiveness and metastatic potential (Church et al., 2003, Fujita et al., 1998, Tsujii et al., 1997). Much of the evidence describing the role of COX-2 in carcinogenesis derives from observing the actions of COX-2 inhibitors. The direct tumoral effects of COX-2 inhibitors may be related to the inhibition of COX-mediated synthesis of PGE2, which has been shown to increase tumour cell proliferation, decrease apoptosis, increase angiogenesis and increase chemo- and radio-resistance (Park et al., 2014). The interactions between tumour and host cells are mediated by growth factors and cytokines, which act as paracrine factors for endothelial and stromal cells (Tanaka et al., 2012). Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to decrease serum markers of inflammation including C-reactive protein (CRP), interleukin-6 (IL-6) and tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) in patients with advanced cancer (Senovilla et al., 2012).

Cyclo-oxygenase inhibitors have therefore been proposed as an option for chemoprevention of colorectal cancer. Both selective inhibitors (such as celecoxib) and nonspecific inhibitors (for example aspirin) reduced the incidence of colorectal cancer (Flossmann et al., 2007, Chan et al., 2005) and the incidence of and recurrence of adenomatous polyps, established as precursors of colorectal cancer, were inversely associated with the regular use of NSAIDs (Tangrea et al., 2003, Johnson et al., 2010).

## **Moderation of the Inflammatory Response in Colorectal Cancer**

Attempts have been made to manipulate the inflammatory response in colorectal cancer and there is epidemiological evidence to support the roles of lifestyle, medication use and diet in colorectal cancer risk and its prevention (Chan and Giovannucci, 2010).

A recent meta-analysis found that aspirin use is associated with a pooled risk ratio of 0.83 (95% CI, 0.72-0.96) for any adenoma and 0.72 (95% CI, 0.57-0.90) for advanced adenomas (Cole et al., 2009) although there was evidence of between-study heterogeneity ( $I^2 = 60.1\%$  for any adenoma and  $65.4\%$  for advanced lesions). Other randomised control trials found that long-term use of aspirin protects against colorectal cancer in a dose-dependent manner (Flossmann et al., 2007). There have been many observational studies supporting the role of non-aspirin and non-COX-2 selective NSAIDs in colorectal cancer prevention; however, randomised trial data are limited. The most compelling hypothesis on the proposed mechanisms by which NSAIDs reduce the risk of colorectal neoplasia is related to their anti-inflammatory effect via the inhibition of COX-2. Moderation of the inflammatory response with medications such as aspirin and non-steroidal anti-inflammatory drugs are associated with substantial reductions in colorectal cancer risk although their utility may be affected by the associated risks and side-effect profile such as bleeding, peptic ulceration and cardiovascular events with COXIBs .

The role of environmental factors in the development of colorectal cancer is supported by the global variation in the incidence of CRC and its change on migration (Ladabaum et al., 2014). Many of the lifestyle risk factors associated with CRC including obesity, low levels of physical activity, alcohol consumption and smoking are associated with the activation of one or more of the above inflammatory pathways. An inverse association between levels of physical activity and the risk of colon cancer has been one of the most consistently observed

(Colbert et al., 2001, Colditz et al., 1997) with a recent meta-analysis demonstrating that physically active individuals had a 20-30% lower risk of colon cancer compared to less active individuals (Wolin et al., 2009). The mechanisms by which physical activity reduces the risk of CRC are not yet fully understood, however, it may be in part due to a reduction in systemic inflammation which is largely mediated through the inhibition of COX-2 (Chan and Giovannucci, 2010).

The second World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) report advised that there is convincing evidence that red meat and processed-meat intake and higher alcohol intake are associated with a higher colorectal cancer risk whilst dietary fibre is associated with a lower risk. The evidence that milk and calcium as well as non-starchy vegetables, fruit and fish are associated with a lower risk of colorectal cancer is less convincing. Whilst there are several suggested mechanisms by which alteration of dietary intake may act to reduce the risk of colorectal cancer, including anti-oxidant and gut modulatory properties, an anti-inflammatory effect exerted by certain dietary compounds appears to play an important role.

Another mechanism by which dietary components may be linked to the development of colorectal cancer may involve the intestinal microbiota. Several studies have found differences in the population of bacteria in those with and those without CRC (Azcarate-Peril et al., 2011) and intestinal microbes may act as pro-carcinogens by inducing pro-inflammatory cytokines, whilst dietary modification can alter the number and type of micro-organisms present.

### **Polyphenols and cancer associated inflammation**

Polyphenols are phytochemicals abundant in plant foods and can be considered as 4 main classes: flavonoids, phenolic acids, stilbenes and lignans. Polyphenolic compounds are

characterised by a benzene ring with one or more hydroxyl groups attached and can be isolated from plant sources including fruits and vegetables, berries and seeds and some beverages such as tea, green tea, red wine and coffee. Dietary polyphenols have been shown to have anti-carcinogenic and anti-inflammatory effects through various mechanisms involving signalling cascades and transcription factors (Marzocchella et al., 2011).

The biological effects of polyphenols that contribute to their role in the inhibition of carcinogenesis include anti-oxidant, anti-inflammatory and phytoestrogenic properties and an ability to inhibit cellular proliferation, invasion, angiogenesis and metastasis and promote apoptosis (Qu et al., 2005, Danbara et al., 2005).

Flavonoids are ingested as part of a normal diet and it is therefore logical that they have been suggested to play a role in the modulation of intestinal inflammation. The bioavailability of polyphenolic compounds is low and therefore they remain in the lumen where they are degraded and metabolised by gut bacteria to phenolic metabolites. Administration of polyphenols was effective at preventing and treating intestinal inflammation in rodents models of IBD where acute or chronic colitis was induced by intra-rectal administration of dinitrobenzene sulphate (Oz et al., 2005, Kim et al., 2005) and addition of dextran sulphate sodium (DSS) to drinking water (Camuesco et al., 2004).

Several *in vivo* animal studies have been performed with naturally occurring polyphenols demonstrating their therapeutic effects in different disease models, particularly those with where an inflammatory component is pertinent. One such example is Rheumatoid Arthritis, and various flavonoids and related polyphenols have been demonstrated to reduce arthritis induced inflammation (Wang et al., 2008, Elmali et al., 2007, Tang et al., 2007). Cardiovascular disease is another condition which evidence suggests is prevented by dietary polyphenolic compounds and the mechanisms by which they exert this action appears to be at

least in part anti-inflammatory because the levels of ICAM-1 and VCAM-1 in atherosclerotic blood vessels were reduced (Gonzalez et al., 2011).

Although the literature is still lacking evidence from trials involving human subjects, several human studies have reported that polyphenolic compounds may reduce the secretion of pro-inflammatory cytokines (Chun et al., 2008, Bobe et al., 2010a) and the molecular mechanisms by which polyphenols may exert their anti-inflammatory effects are multiple including the attenuation of signal transduction pathways, the cyclooxygenase and lipooxygenase pathways in particular (Wang et al., 2006).

In the context of benign inflammatory disease, a 6-month placebo-controlled trial of curcumin therapy in 89 patients with quiescent ulcerative colitis (UC) found a decreased relapse rate in those who were treated with curcumin (Hanai et al., 2006). Relapse was seen in 5% of those treated with curcumin and 21% of the placebo group.

Of the entire gastrointestinal tract, the large intestine may be exposed to the highest concentration of flavonoids due to their poor availability (Halliwell et al., 2000) and there is a growing body of evidence from human studies that certain polyphenolic compounds are associated with a reduced risk of colorectal cancer (Rossi et al., 2006, Theodoratou et al., 2007). Furthermore, case-control studies comparing dietary polyphenol intake in those diagnosed with colorectal cancer, with a control group, using food frequency questionnaires have demonstrated that the consumption of certain polyphenols was low in CRC cases versus controls and these are outlined in Table 2.

This presents an interesting concept, that dietary alteration to a diet high in polyphenols such as fruits and vegetables, berries, tea and coffee may be effective in modulating inflammatory responses and therefore decreasing the risk of advanced and high-risk colorectal adenoma recurrence (Bobe et al., 2010a, Bobe et al., 2008) and colorectal cancer (Rossi et al., 2006, Theodoratou et al., 2007) without the adverse effects that have been



associated with some of the agents currently under investigation for chemoprevention in colorectal carcinogenesis.

### **The effect of polyphenols on signal transduction pathways important in tumour growth and inflammation in CRC**

The anti-inflammatory activities of polyphenols can be related to the arachidonic acid-dependent pathway (COX, lipo-oxygenase and phospholipase A2 inhibition) or arachidonic independent pathways involving nitrous oxide synthase (NOS), NF- $\kappa$ B and NAG (Biesalski, 2007). Despite this, the evidence for polyphenols as anti-inflammatory agents remains limited and most studies have been performed *in vitro* and have concentrated on one specific polyphenolic compound (Table 1).

#### ***NF- $\kappa$ B***

Dietary polyphenols such as resveratrol (Manna et al., 2000), green tea catechins (Yang et al., 2001) and curcumin (Singh and Aggarwal, 1995) are potent inhibitors of the NF- $\kappa$ B signalling pathway in human and animal cell lines *in vitro* and the mechanisms by which they exert this effect are becoming better understood. These substances may intervene at any step in the NF- $\kappa$ B signalling pathway, for example, inhibition of the translocation of NF- $\kappa$ B to the nucleus or inhibition of any of the initial stimulatory signal transduction pathways or transcription factors. Curcumin (the main polyphenolic in turmeric) is one such example which has been shown to mediate its chemotherapeutic effects by NF- $\kappa$ B inhibition and by inhibition of NF- $\kappa$ B regulated gene products such as COX-2, adhesion molecules, MMPs, iNOS, Bcl-2 and TNF (Shishodia et al., 2005).

### *STAT*

Dietary polyphenols epigallocatechin-3-gallate (EGCG) from green tea (Masuda et al., 2001), resveratrol (Wung et al., 2005) and curcumin (Bharti et al., 2003) have been shown to suppress the activation of STAT in tumour cells in human malignancy. EGCG was shown to down-regulate the phosphorylation of STAT3 whilst resveratrol inhibited IL-6 induced ICAM-1 gene expression partly by interfering with STAT3 phosphorylation.

### *PI3k*

There is little in the way of evidence to support the inhibition of PI3k by polyphenolic compounds. Li et al demonstrated down-regulation of the oncogene MDM2 by curcumin via the PI3K signalling pathway and when activated, this pathway is known to promote cell survival and proliferation (Li et al., 2007). This effect was noted in human cancer cell lines as well as normal cell lines. Further work on colorectal cancer cells treated with curcumin demonstrated an inhibitory effect on cell growth in a time and dose-dependent manner via the PI3k/Akt pathway (Johnson et al., 2009).

Another polyphenol, quercetin, has been shown to exert a protective effect against COX-2 expression and PGE2 production by targeting the PI3K signalling pathway in rat liver epithelial cells and this may contribute to its chemopreventive potential (Lee et al., 2010).

### *Cyclo-oxygenase*

Dietary polyphenols have been shown to exert their anti-inflammatory effects through inhibition of COX-2 at the transcriptional and enzyme level (Biesalski, 2007). Many dietary polyphenols have demonstrated this ability to inhibit COX-2 in vitro including green tea

extract enriched with catechin and epigallocatechin gallate (EGCG) which inhibited COX-2 expression in mouse skin (Kundu et al., 2003) and genistein, quercetin, kaempferol and resveratrol were found to down-regulate COX-2 promoter activity in human colon cancer cells (Mutoh et al., 2000).

NSAID activated gene-1 is a member of the TGF- $\beta$  superfamily proteins and is another factor involved in the inflammatory response. It is activated by NSAIDs and also by several dietary compounds. Induction of NAG-1 can induce apoptosis and promote anti-tumorigenic activity (Baek et al., 2004). Baek et al have demonstrated that green tea polyphenol, epicatechin gallate, induces the expression of NAG-1 in colon cancer cells (Baek et al., 2004).

**Table 1: Mechanisms of chemoprevention by polyphenols in *in vitro* cell lines**

Authors	Cell Type	Poyphenol (s)	Outcomes
Kundu et al (2003) (Kundu et al., 2003)	Mouse skin	Catechin Epigallocatechin gallate	Inhibition of COX-2 expression
Mutoh et al (2000) (Mutoh et al., 2000)	Human colon cancer DLD-1 cells	Quercetin, kaempferol, genistein, resveratrol, resorcinol	Inhibition of COX-2 expression
Suh et al (2009) (Suh et al., 2009)	Human colon cancer HT29 cells	Fisetin	Apoptosis & down regulation of COX-2 protein expression in colon cancer cells
Li et al (2007) (Li et al., 2007)	Human prostate cancer cell lines	Curcumin	Reduced oncogene MDM2 via PI3K signalling
Johnson et al (2009) (Johnson et al., 2009)	Colorectal cancer cells	Curcumin	Inhibitory effect on cell growth via PI3K/Akt pathway
Lee et al (2010) (Lee et al., 2010)	Rat liver epithelial cells	Quercetin	Protective effect of quercetin against COX-2 expression by

			targeting PI3K
Manna et al (2000) (Manna et al., 2000)	Human cells lines (lymphoma, epithelial cells)	Resveratrol	Inhibition of TNF induced activation of NF- $\kappa$ B
Singh et al (1995) (Singh and Aggarwal, 1995)	Human leukaemia cell line	Curcumin	Inhibition of NF- $\kappa$ B
Yang et al (2001) (Yang et al., 2001)	Rat intestinal epithelial cell line	EGCG	Inhibition of I kappa B kinase complex mediated activation of NF- $\kappa$ B
Bharti et al (2003) (Bharti et al., 2003)	Human malignant melanoma cell lines	Curcumin	Inhibition of IL-6 induced STAT3 phosphorylation
Masuda et al (Masuda et al., 2001)	Head and neck squamous cell carcinoma cell line	EGCG	Suppression of the activation of STAT3
Wung et al (2005) (Wung et al., 2005)	Bovine aortic endothelial cells	Resveratrol	Inhibition of phosphorylation and of activation of STAT3
Baek et al (2004) (Baek et al., 2004)	Human colon cancer cells (HCT-116)	Catechins	ECG induced expression of NAG-1
Martinez-Florez et al (2005) (Martinez-Florez et al., 2005)	Rat hepatocytes	Quercetin	Inhibition of iNOS expression by quercetin

### **Polyphenols & the systemic inflammatory response**

Cytokine concentrations measured in the serum or in the tumour itself may be utilised as markers of inflammation and may be an indicator of the risk of neoplastic change or

progression (Pellegrini et al., 2006). In human studies, elevated serum levels of IL-6, CRP and TNF- $\alpha$  were associated with the presence of colorectal adenomas (Kim et al., 2008).

### *Interleukin-6*

Interleukin-6 is a pro-inflammatory cytokine, the primary source of which are monocytes and macrophages during acute inflammation and T cells during chronic inflammation and it may act as a tumour promoter in colorectal neoplasms (Naugler and Karin, 2008, Heikkila et al., 2008). Activation of IL-6 activates Janus kinases (JAK) and STATs, which are involved in the regulation of cell proliferation and apoptosis (Hodge et al., 2005). There is a growing body of evidence that IL-6 is over-expressed in colorectal cancer tissue (Chung et al., 2006, Kinoshita et al., 1999) and, further to this, increased concentrations of IL-6 were associated with poorer survival and high-risk pathological factors such as T-stage, nodal status and vascular invasion (Chung et al., 2006). Similarly, there is reliable evidence that circulating concentrations of IL-6 are elevated in patients with colorectal cancer when compared to normal controls and, again, this is associated with poorer survival, tumour size and T-stage (Belluco et al., 2000, Galizia et al., 2002, Chung and Chang, 2003, Nikiteas et al., 2005). In addition to colorectal adenocarcinoma, IL-6 concentrations were also associated positively with the presence of colorectal adenoma in a colonoscopy-based study in North Carolina (Kim et al., 2008).

The evidence in humans that the consumption of dietary polyphenols decreases circulating levels of inflammatory markers such as IL-6 remains inconclusive (Song et al., 2005, Chun et al., 2008). Recently, Bobe et al (Bobe et al., 2010a) investigated whether serum IL-6 was associated with colorectal adenoma recurrence and flavonol intake in order to determine whether measuring serum levels would serve as an indicator of risk or recurrence. They found that a high intake of flavonols was inversely associated with serum IL-6

concentrations and advanced and high risk adenoma recurrence and concluded that dietary flavonols could serve as a method to prevent colorectal cancer and that serum IL-6 levels may serve as an indicator of risk and of response (Bobe et al., 2010a).

### ***CRP***

C-reactive protein is a nonspecific marker of systemic inflammation and it has been widely used to detect and monitor systemic inflammatory responses with extensive research supporting the fact that CRP levels are higher in cancer patients than healthy subjects. Several large cohort studies have identified a link between pre-cancer inflammation as measured by the CRP and colorectal cancer risk (Prizment et al., 2011, Allin et al., 2009). Furthermore, the systemic inflammatory response measured by circulating CRP levels, is a predictor of recurrence and overall survival in those with colorectal cancer.


Population-based observational and randomised control trials have found that an inverse relationship between the serum CRP concentration and dietary intake of substances high in polyphenols exists (De Bacquer et al., 2006, Steptoe et al., 2007, Chun et al., 2008). Chun et al (Chun et al., 2008) analysed the dietary flavonoid intakes of over 8000 American adults. Total flavonoid and individual flavonoid compounds (quercetin, kaempferol, malvidin, peonidin, daidzein and genistein) had inverse associations with serum CRP concentration.

### ***TNF***

TNF is produced during the initial inflammatory response, initiating the production of cytokines and chemokines and increasing vascular permeability therefore promoting inflammation, angiogenesis and tumour dissemination (Li et al., 2009, Balkwill, 2009). Its expression increases during colon tumorigenesis and interference with TNF signalling with a soluble decoy receptor decreased tumorigenicity and tumour growth (Popivanova et al.,

2008). Polyphenol ellagic acid has been shown to reduce the expression of COX-2, iNOS, IL-6 and TNF- $\alpha$  in a rat model of colon cancer (Umesalma and Sudhandiran, 2010).

Other studies have reported that concentrations of IL-8, IL-10, IL-12, granulocyte macrophage colony stimulating factor (GM-CSF) and TNF- $\alpha$  are higher in those individuals with colorectal adenomas (Berghella et al., 1997) however, more recent studies were unable to associate serum concentration of IL-1, 2, 8, 10, GM-CSF, IF- $\gamma$  or TNF- $\alpha$  with an elevated risk of colorectal adenoma recurrence, despite decrease cytokine concentrations during high flavonol consumption (Bobe et al., 2010b).



**Figure 2: Mechanisms of inhibition of inflammation in cancer by dietary polyphenols**

Signal transducer and activation of transcription 3 (STAT3) and nuclear factor- $\kappa$ B (NF- $\kappa$ B) are induced in cancer cells by pro-inflammatory cytokines. This results in the suppression of apoptosis and the promotion of cell cycle progression and cell proliferation. Various dietary polyphenolic compounds have been demonstrated

to inhibit these inflammatory pathways (🚫), ultimately reducing cancer-associated inflammation and therefore reducing the incidence of neoplasia.

### **Dietary Polyphenols and Colorectal Neoplasia Risk in Observational Studies**

There is epidemiological evidence from a limited number of case-control and cohort studies (Table 2), which have assessed the relationship between dietary flavonoid intake and colorectal cancer or colorectal adenomas. Flavonols are one class of dietary polyphenols that have been investigated for their ability to reduce the risk of colorectal adenoma recurrence in the Polyp Prevention Trial (Bobe et al., 2008). Bobe and colleagues found that a higher intake of flavonols was associated with a 76% decrease in the risk of advanced adenoma recurrence. They hypothesised that this may also apply in colorectal adenocarcinoma given that in cell culture more progressed tumour cells were more sensitive to flavonols (Jeong et al., 2009).

**Table 2: Clinical studies reporting an association between intake of dietary polyphenols and colorectal cancer/adenoma risk**

<b>Authors</b>	<b>Sample Size</b>	<b>Methods</b>	<b>Outcomes</b>	<b>Association</b>	<b>Strength of Association</b>
Akhter et al (2008) (Akhter et al., 2008)	886	Prospective cohort study	Association of isoflavone intake with CRC risk	Intake of isoflavones is associated with reduced risk of proximal colon cancer in men only	HR in highest quartile 0.55 (5% CI 0.33-0.92) for proximal cancer in men only (P=0.007)
Akhter (2009) (Akhter et al., 2009)	721 cases 697 controls	Case-control study	Association of isoflavone intake & colorectal adenoma risk	There is an inverse association between dietary isoflavone intake and colorectal	OR 0.7 (95% CI 0.51-0.96) for highest vs lowest quartile of isoflavone intake P=0.03 overall and



				adenoma and it was more pronounced in women	0.49 (0.27-0.90) in women (P=0.03)
Arts (2002) (Arts et al., 2002)	33,339 (635 colon cancers)	Cohort study	Association of dietary catechin intake and cancer incidence amongst postmenopausal women	Rectal cancer but not colon cancer was inversely associated with catechin intake	RR 0.55 for highest quartile of intake (P= 0.02) for rectal cancer only
Bobbe (2008) (Bobbe et al., 2008)	958 cases 947 controls	Randomised, multicentre nutritional intervention trial	Association of flavonoids with adenoma recurrence	High intake of flavonols and isoflavonoids were associated with reduced incidence of advanced adenoma recurrence	OR 0.24 (95% CI 0.11-0.53) for highest vs lowest quartile for flavonols (P=0.0006) & 0.46 (0.22-0.95) for isoflavonoids (P=0.01)
Budhathoki (2011) (Budhathoki et al., 2011)	816 cases 815 controls	Case-control study	Association of soy food and isoflavone intake and CRC risk	High intake of soy food and isoflavones were inversely associated with colorectal cancer risk in men and post-menopausal women	OR for highest vs lowest quintile 0.65 (95% CI 0.41-1.03), p=0.03 for soy foods & 0.68 (0.42-1.10) p= 0.051 for isoflavones in men & 0.60 (0.29-1.25) p=0.053 & 0.68 (0.33-1.40) p= 0.049 in postmenopausal women
Cotterchio (2006) (Cotterchio et al., 2006)	1095 cases 1890 controls	Case-control study	Association of dietary phytoestrogens and colorectal cancer risk	Dietary lignan and isoflavone intake were associated with reduced risk of colorectal cancer	OR 0.73 (95% CI 0.56-0.94) p= 0.01 for highest vs lowest lignan intake & 0.71 (0.58-0.86) p<0.01 for isoflavones
Djuric (2012) (Djuric et al., 2012)	1163 cases 1501 controls	Case-control study	Association of dietary intake of quercetin and risk of colorectal cancer	Protective effective of quercetin on risk of proximal colon cancer only when fruit intake high and tea intake low	OR 0.49 (95% CI 0.32-0.73) P=0.006) with high fruit intake, 0.44 (0.27-0.72) P= 0.003 with high healthy eating index & 0.51 (0.26-1.00) P=0.044 when tea intake was low
Kyle (2010) (Kyle et al., 2010)	264 cases 408 controls	Case-control study	Evaluation of the association of four flavonoid subclasses and the risk of colorectal cancer	Non-tea flavonol, specifically quercetin were associated with reduced colorectal cancer risk	OR 0.6 (95% CI 0.4-1.0) for non-tea flavonol & 0.5 (0.3-0.8) P<0.01 for colon cancer with high levels of non-tea quercetin intake
Rossi (2006) (Rossi et al., 2006)	1953 cases 4154 controls	Case-control study	Association of flavonoid intake and colorectal cancer risk	Reduced risk colorectal cancer with high intake isoflavones, anthocyanidins, flavones,	OR 0.76 (95% CI 0.63-0.91) P=0.001 for isoflavones, 0.67 (0.54-0.82) P<0.001 for anthocyanidins,

				flavonols	0.78 (0.65-0.93) P=0.004 for flavones, 0.64 (0.54-0.77) P<0.001 for flavonols
Simons (2009) (Simons et al., 2009)	2485 cases	Cohort study	Association of flavonol, flavones & catechin intake with CRC risk	Total catechin and epicatechin intake was associated with rectal cancer in men with BMI>25 and total catechin, kaempferol, myricetin was associated with colorectal cancer in women BMI<25	Total catechin/epicatechin in male rectal cancer with BMI>25 HR 0.63 (0.36-1.08) P=0.04. Total catechin in female colon cancer with BMI<25 HR= 0.62 (0.43-0.91) P=0.04 for highest vs lowest quintiles
Theodoratou (2007) (Theodoratou et al., 2007)	1456 cases 1456 controls	Case-control study	Association of flavonoid intake with CRC risk	Increased consumption of flavonols, quercetin, catechin & epicatechin were associated with a reduction in colorectal cancer risk	OR 0.73 P=0.0121 for flavonols, 0.68 P=0.001 for quercetin, 0.68 P<0.0005 for catechin, 0.74, P=0.019 for epicatechin & 0.78 P=0.031 for procyanidins.
Ward (2010) (Ward et al., 2010)	221 cases 886 controls	Case-control study	Association of risk of colorectal cancer relative to phyto-oestrogen intake	Colorectal cancer risk was inversely associated with enterolactone & entrolignans in women only	OR 0.33 (0.14-0.74) P=0.008 for enterolactone & 0.32 (0.13-0.79) P=0.013 for enterolignans
Yang, G (2009) (Yang et al., 2009)	68412 (321 CRC)	Cohort study	The relationship between intake of soy foods/isoflavones and colorectal cancer risk	Soy foods/isoflavones reduced the risk of colorectal cancer in postmenopausal women	RR 0.67 (95% CI 0.49-0.90) for highest vs lowest tertile p=0.008
Zamora-Ros (2013) (Zamora-Ros et al., 2013)	424 cases 401 controls	Case-control study	Relationship between dietary flavonoid and lignin intakes and the risk of colorectal cancer	Intake of total dietary flavonoids and lignans was inversely associated with colorectal cancer risk	OR 0.59 95% CI 0.35-0.99) for flavonoids P=0.04, 0.59 (0.34-0.99) for lignans P=0.03

Hoensch and colleagues investigated the recurrence risk of neoplasia in patients with resected colorectal cancer and after polypectomy in those who were treated with a mixture of flavonoids (apigenin and epigallocatechin-gallate) as compared to a matched control group.

36 patients had resected colon cancer and 51 had undergone polypectomy (Hoensch et al., 2008). Both the treated group and the untreated controls were monitored with a surveillance colonoscopy for 3-4 years and also by questionnaire. The combined recurrence rate for neoplasia (cancer and adenoma) was 7% in the treated group compared to 47% in the control group. Therefore, they concluded that treatment with flavonoids could reduce the recurrence rate of neoplasia in those with resected colon cancer.

## **Conclusion**

Over the past decade there has been an increased appreciation that inflammation has a significant role to play in human carcinogenesis and there is a significant body of evidence to support the role of the host inflammatory response in the progression of cancer of the colon and rectum. Various methods of favourably manipulating cancer-associated inflammation have shown promise including aspirin, statins and other non-steroidal anti-inflammatory drugs. Lifestyle factors also play a role in the development of colorectal cancer including obesity, lack of exercise, alcohol consumption and dietary intake. Further to this, dietary polyphenolic compounds have been shown to act at multiple key steps in carcinogenesis and therefore a role in colorectal cancer prevention has been suggested.

The current evidence from epidemiological studies on the association of dietary flavonol intake and colorectal cancer or adenoma risk is limited and much of the current research concentrates on isolated flavonoids. Although positive associations between a reduction in risk and many polyphenolic compounds have been demonstrated, the data is inconsistent and many find this positive association with only one compound out of several tested.

As there are relatively few human studies at the time of writing conferring the benefit of a diet rich in polyphenols in those who have colorectal adenomas or adenocarcinoma, it would be premature to suggest a major public health intervention to promote their consumption. However, dietary change is both safe and feasible and this emphasises the need for further investigation of dietary polyphenols and their association with colorectal cancer risk. This data would be essential in formulating dietary recommendations for the general public and for those who are at an increased risk of colorectal adenoma or carcinoma and this may complement the current bowel screening programme to work towards a shift to earlier stage diagnosis of colorectal cancer.

## References

- <http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/survival/#stage>.
- AGGARWAL, B. B. & SHISHODIA, S. 2006. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochemical Pharmacology*, 71, 1397-1421.
- AKHTER, M., INOUE, M., KURAHASHI, N., IWASAKI, M., SASAZUKI, S., TSUGANE, S. & PROSPE, J. P. H. C. B. 2008. Dietary soy and isoflavone intake and risk of colorectal cancer in the Japan public health center-based prospective study. *Cancer Epidemiology Biomarkers & Prevention*, 17, 2128-2135.
- AKHTER, M., IWASAKI, M., YAMAJI, T., SASAZUKI, S. & TSUGANE, S. 2009. Dietary isoflavone and the risk of colorectal adenoma: a case-control study in Japan. *British Journal of Cancer*, 100, 1812-1816.
- ALLIN, K. H., BOJESEN, S. E. & NORDESTGAARD, B. G. 2009. Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer. *Journal of Clinical Oncology*, 27, 2217-2224.
- ARTS, I. C. W., JACOBS JR, D. R., GROSS, M., HARNACK, L. J. & FOLSOM, A. R. 2002. Dietary catechins and cancer incidence among postmenopausal women: the Iowa Women's Health Study (United States). *Cancer Causes & Control*, 13, 373-382.
- AZCARATE-PERIL, M. A., SIKES, M. & BRUNO-BARCENA, J. M. 2011. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 301, G401-G424.
- BAEK, S. J., KIM, J. S., JACKSON, F. R., ELING, T. E., MCENTEE, M. F. & LEE, S. H. 2004. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. *Carcinogenesis*, 25, 2425-2432.
- BALKWILL, F. 2009. Tumour necrosis factor and cancer. *Nature Reviews Cancer*, 9, 361-371.
- BARAL, R., BOSE, A., RAY, C., PAUL, S., PAL, S., HAQUE, E., MISHRA, B., PAL, D., NAGPAL, J. K., PANDA, C. K. & DAS, B. R. 2009. Association of early phase of colorectal carcinogenesis with STAT3 activation and its relevance in apoptosis regulation. *Experimental and Molecular Pathology*, 87, 36-41.
- BARAULT, L., VEYRIE, N., JOOSTE, V., LECORRE, D., CHAPUSOT, C., FERRAZ, J. M., LIEVRE, A., CORTET, M., BOUVIER, A. M., RAT, P., ROIGNOT, P., FAIVRE, J., LAURENT-PUIG, P. & PIARD, F. 2008. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. *International Journal of Cancer*, 122, 2255-2259.
- BELLUCO, C., NITTI, D., FRANTZ, M., TOPPAN, P., BASSO, D., PLEBANI, M., LISE, M. & JESSUP, J. M. 2000. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. *Annals of Surgical Oncology*, 7, 133-138.
- BERGHELLA, A. M., PELLEGRINI, P., DELBEATO, T., ADORNO, D. & CASCIANI, C. U. 1997. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer. *Cancer Biotherapy and Radiopharmaceuticals*, 12, 265-272.
- BHARTI, A. C., DONATO, N. & AGGARWAL, B. B. 2003. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. *Journal of Immunology*, 171, 3863-3871.
- BIESALSKI, H. K. 2007. Polyphenols and inflammation: basic interactions. *Curr Opin Clin Nutr Metab Care*, 10, 724-728.
- BINGHAM, S. A., DAY, N. E. & LUBEN, R. 2003. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study (vol 361, pg 1496, 2003). *Lancet*, 362, 1000-1000.
- BOBE, G., ALBERT, P. S., SANBURY, L. B., LANZA, E., SCHATZKIN, A., COLBURN, N. H. & CROSS, A. J. 2010a. Interleukin-6 as a Potential Indicator for Prevention of High-Risk Adenoma

- Recurrence by Dietary Flavonols in the Polyp Prevention Trial. *Cancer Prevention Research*, 3, 764-775.
- BOBE, G., MURPHY, G., ALBERT, P. S., SANSBURY, L. B., LANZA, E., SCHATZKIN, A., COLBURN, N. H. & CROSS, A. J. 2010b. Serum cytokine concentrations, flavonol intake and colorectal adenoma recurrence in the Polyp Prevention Trial. *British Journal of Cancer*, 103, 1453-1461.
- BOBE, G., SANSBURY, L. B., ALBERT, P. S., CROSS, A. J., KAHLE, L., ASHBY, J., SLATTERY, M. L., CAAN, B., PASKETT, E., IBER, F., KIKENDALL, J. W., LANCE, P., DASTON, C., MARSHALL, J. R., SCHATZKIN, A. & LANZA, E. 2008. Dietary flavonoids and colorectal adenoma recurrence in the polyp prevention trial. *Cancer Epidemiology Biomarkers & Prevention*, 17, 1344-1353.
- BUDHATHOKI, S., JOSHI, A. M., OHNAKA, K., YIN, G., TOYOMURA, K., KONO, S., MIBU, R., TANAKA, M., KAKEJI, Y., MAEHARA, Y., OKAMURA, T., IKEJIRI, K., FUTAMI, K., MAEKAWA, T., YASUNAMI, Y., TAKENAKA, K., ICHIMIYA, H. & TERASAKA, R. 2011. Soy food and isoflavone intake and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. *Scand J Gastroenterol*, 46, 165-72.
- BURKITT, D. P. 1969. Related Disease - Related Cause. *Lancet*, 2, 1229-&.
- CAIRNS, S. R., SCHOLEFIELD, J. H., STEELE, R. J., DUNLOP, M. G., THOMAS, H. J. W., EVANS, G. D., EADEN, J. A., RUTTER, M. D., ATKIN, W. P., SAUNDERS, B. P., LUCASSEN, A., JENKINS, P., FAIRCLOUGH, P. D., WOODHOUSE, C. R. J., GASTROENTEROLOGY, B. S. & IR, A. C. G. B. 2010. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut*, 59, 666-689.
- CAMUESCO, D., COMALADA, M., RODRIGUEZ-CABEZAS, M. E., NIETO, A., LORENTE, M. D., CONCHA, A., ZARZUELO, A. & GALVEZ, J. 2004. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. *Br J Pharmacol*, 143, 908-918.
- CHAN, A. T. & GIOVANNUCCI, E. L. 2010. Primary Prevention of Colorectal Cancer. *Gastroenterology*, 138, 2029-U40.
- CHAN, A. T., GIOVANNUCCI, E. L., MEYERHARDT, J. A., SCHERNHAMMER, E. S., CURHAN, G. C. & FUCHS, C. S. 2005. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. *Jama-Journal of the American Medical Association*, 294, 914-923.
- CHAN, D., LAU, R., AUNE, D., VIEIRA, R., GREENWOOD, D., KAMPMAN, E. & NORAT, T. 2011. The Wcrf/Aicr Continuous Update Project: Dietary Fibre Intake and Colorectal Cancer Incidence. *Journal of Epidemiology and Community Health*, 65, A97-A97.
- CHO, E. Y., SMITH-WARNER, S. A., RITZ, J., VAN DEN BRANDT, P. A., COLDITZ, G. A., FOLSOM, A. R., FREUDENHEIM, J. L., GIOVANNUCCI, E., GOLDBOEHM, R. A., GRAHAM, S., HOLMBERG, L., KIM, D. H., MALILA, N., MILLER, A. B., PIETINEN, P., ROHAN, T. E., SELLERS, T. A., SPEIZER, F. E., WILLETT, W. C., WOLK, A. & HUNTER, D. J. 2004. Alcohol intake and colorectal cancer: A pooled analysis of 8 cohort studies. *Annals of Internal Medicine*, 140, 603-613.
- CHUN, O. K., CHUNG, S. J., CLAYCOMBE, K. J. & SONG, W. O. 2008. Serum c-reactive protein concentrations are inversely associated with dietary flavonoid intake in US adults. *Journal of Nutrition*, 138, 753-760.
- CHUNG, Y. C., CHAEN, Y. L. & HSU, C. P. 2006. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. *Anticancer Research*, 26, 3905-3911.
- CHUNG, Y. C. & CHANG, Y. F. 2003. Serum interleukin-6 levels reflect the disease status of colorectal cancer. *Journal of Surgical Oncology*, 83, 222-226.
- CHURCH, R. D., FLESHMAN, J. W. & MCLEOD, H. L. 2003. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. *British Journal of Surgery*, 90, 1055-1067.
- COLBERT, L. H., HARTMAN, T. J., MALILA, N., LIMBURG, P. J., PIETINEN, P., VIRTAMO, J., TAYLOR, P. R. & ALBANES, D. 2001. Physical activity in relation to cancer of the colon and rectum in a cohort of male smokers. *Cancer Epidemiology Biomarkers & Prevention*, 10, 265-268.
- COLDITZ, G. A., CANNUSCIO, C. C. & FRAZIER, A. L. 1997. Physical activity and reduced risk of colon cancer: implications for prevention. *Cancer Causes & Control*, 8, 649-667.

- COLE, B. F., LOGAN, R. F., HALABI, S., BENAMOUZIG, R., SANDLER, R. S., GRAINGE, M. J., CHAUSSADE, S. & BARON, J. A. 2009. Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials. *Journal of the National Cancer Institute*, 101, 256-266.
- COLOTTA, F., ALLAVENA, P., SICA, A., GARLANDA, C. & MANTOVANI, A. 2009. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis*, 30, 1073-81.
- COTTERCHIO, M., BOUCHER, B. A., MANNO, M., GALLINGER, S., OKEY, A. & HARPER, P. 2006. Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. *Journal of Nutrition*, 136, 3046-53.
- CUI, G. & FLORHOLMEN, J. 2008. Polarization of cytokine profile from Th1 into Th2 along colorectal adenoma-carcinoma sequence: implications for the biotherapeutic target? *Inflamm Allergy Drug Targets*, 7, 94-7.
- DANBARA, N., YURI, T., TSUJITA-KYUTOKU, M., TSUKAMOTO, R., UEHARA, N. & TSUBURA, A. 2005. Enterolactone induces apoptosis and inhibits growth of colo 201 human colon cancer cells both in vitro and in vivo. *Anticancer Research*, 25, 2269-2276.
- DE BACQUER, D., CLAYS, E., DELANGHE, J. & DE BACKER, G. 2006. Epidemiological evidence for an association between habitual tea consumption and markers of chronic inflammation. *Atherosclerosis*, 189, 428-435.
- DIMBERG, J., SAMUELSSON, A., HUGANDER, A. & SODERKVIST, P. 1999. Differential expression of cyclooxygenase 2 in human colorectal cancer. *Gut*, 45, 730-732.
- DJURIC, Z., SEVERSON, R. K. & KATO, I. 2012. Association of Dietary Quercetin With Reduced Risk of Proximal Colon Cancer. *Nutrition and Cancer-an International Journal*, 64, 351-360.
- ELLUL, P., FOGDEN, E., SIMPSON, C. L., NICKERSON, C. L. R., MCKAIG, B. C., SWARBRICK, E. T. & VEITCH, A. M. 2010. Downstaging of colorectal cancer by the national bowel cancer screening programme in England: first round data from the first centre. *Colorectal Disease*, 12, 420-422.
- ELMALI, N., BAYSAL, O., HARMA, A., ESENKAYA, I. & MIZRAK, B. 2007. Effects of resveratrol in inflammatory arthritis. *Inflammation*, 30, 1-6.
- FEARON, E. R. 2011a. Molecular genetics of colorectal cancer. *Annu Rev Pathol*, 6, 479-507.
- FEARON, E. R. 2011b. Molecular Genetics of Colorectal Cancer. *Annual Review of Pathology: Mechanisms of Disease, Vol 6*, 6, 479-507.
- FLOSSMANN, E., ROTHWELL, P. M. & TRIAL, B. D. A. 2007. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. *Lancet*, 369, 1603-1613.
- FUJITA, T., MATSUI, M., TAKAKU, K., UETAKE, H., ICHIKAWA, W., TAKETO, M. M. & SUGIHARA, K. 1998. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. *Cancer Research*, 58, 4823-4826.
- GALIZIA, G., ORDITURA, M., ROMANO, C., LIETO, E., CASTELLANO, P., PELOSIO, L., IMPERATORE, V., CATALANO, G., PIGNATELLI, C. & DE VITA, F. 2002. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. *Clinical Immunology*, 102, 169-178.
- GONZALEZ, R., BALLESTER, I., LOPEZ-POSADAS, R., SUAREZ, M. D., ZARZUELO, A., MARTINEZ-AUGUSTIN, O. & DE MEDINA, F. 2011. Effects of Flavonoids and other Polyphenols on Inflammation. *Critical Reviews in Food Science and Nutrition*, 51, 331-362.
- HALLIWELL, B., ZHAO, K. C. & WHITEMAN, M. 2000. The gastrointestinal tract: A major site of antioxidant action? *Free Radical Research*, 33, 819-830.
- HANAHAH, D. & WEINBERG, R. A. 2011. Hallmarks of Cancer: The Next Generation. *Cell*, 144, 646-674.
- HANAI, H., IIDA, T., TAKEUCHI, K., WATANABE, F., MARUYAMA, Y., ANDOH, A., TSUJIKAWA, T., FUJIYAMA, Y., MITSUYAMA, K., SATA, M., YAMADA, M., IWAOKA, Y., KANKE, K., HIRAIISHI, H., HIRAYAMA, K., ARAI, H., YOSHII, S., UCHIJIMA, M., NAGATA, T. & KOIDE, Y. 2006. Curcumin

- maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. *Clinical Gastroenterology and Hepatology*, 4, 1502-1506.
- HEIKKILA, K., EBRAHIM, S. & LAWLOR, D. A. 2008. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. *European Journal of Cancer*, 44, 937-945.
- HEWITSON, P., GLASZIOU, P., IRWIG, L., TOWLER, B. & WATSON, E. 2007. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. *Cochrane Database of Systematic Reviews*.
- HODGE, D. R., HURT, E. M. & FARRAR, W. L. 2005. The role of IL-6 and STAT3 in inflammation and cancer. *European Journal of Cancer*, 41, 2502-2512.
- HOENSCH, H., GROH, B., EDLER, L. & KIRCH, W. 2008. Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. *World Journal of Gastroenterology*, 14, 2187-2193.
- INOUE-CHOI, M., ROBIEN, K. & LAZOVICH, D. 2013. Adherence to the WCRF/AICR Guidelines for Cancer Prevention Is Associated with Lower Mortality among Older Female Cancer Survivors. *Cancer Epidemiology Biomarkers & Prevention*, 22, 792-802.
- JEONG, J. H., AN, J. Y., KWON, Y. T., RHEE, J. G. & LEE, Y. J. 2009. Effects of Low Dose Quercetin: Cancer Cell-Specific Inhibition of Cell Cycle Progression. *Journal of Cellular Biochemistry*, 106, 73-82.
- JESS, T., SIMONSEN, J., JORGENSEN, K. T., PEDERSEN, B. V., NIELSEN, N. M. & FRISCH, M. 2012. Decreasing Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease Over 30 Years. *Gastroenterology*, 143, 375-+.
- JOHNSON, C. C., HAYES, R. B., SCHOEN, R. E., GUNTER, M. J., HUANG, W. Y. & TEAM, P. T. 2010. Non-Steroidal Anti-Inflammatory Drug Use and Colorectal Polyps in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *American Journal of Gastroenterology*, 105, 2646-2655.
- JOHNSON, S. M., GULHATI, P., ARRIETA, I., WANG, X. F., UCHIDA, T., GAO, T. Y. & EVERS, B. M. 2009. Curcumin Inhibits Proliferation of Colorectal Carcinoma by Modulating Akt/mTOR Signaling. *Anticancer Research*, 29, 3185-3190.
- KANG, Y. K., YOO, C., RYOO, B. Y., LEE, J. J., TAN, E., PARK, I., PARK, J. H., CHOI, Y. J., JO, J., RYU, J. S. & RYU, M. H. 2013. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. *British Journal of Cancer*, 109, 2309-2315.
- KAUR, J. & SANYAL, S. N. 2010. PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. *Tumor Biology*, 31, 623-631.
- KAWAMORI, T., UCHIYA, N., SUGIMURA, T. & WAKABAYASHI, K. 2003. Enhancement of colon carcinogenesis by prostaglandin E-2 administration. *Carcinogenesis*, 24, 985-990.
- KIM, H., KONG, H. S., CHOI, B., YANG, Y. W., KIM, Y., LIM, M. J., NECKERS, L. & JUNG, Y. J. 2005. Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. *Pharmaceutical Research*, 22, 1499-1509.
- KIM, S., KEKU, T. O., MARTIN, C., GALANKO, J., WOOSLEY, J. T., SCHROEDER, J. C., SATIA, J. A., HALABI, S. & SANDLER, R. S. 2008. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. *Cancer Research*, 68, 323-328.
- KINOSHITA, T., ITO, H. & MIKI, C. 1999. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. *Cancer*, 85, 2526-2531.
- KNUPFER, H. & PREISS, R. 2010. Serum interleukin-6 levels in colorectal cancer patients--a summary of published results. *International Journal of Colorectal Disease*, 25, 135-40.
- KOJIMA, M., MORISAKI, T., SASAKI, N., NAKANO, K., MIBU, R., TANAKA, M. & KATANO, M. 2004. Increased nuclear factor-kappa B activation in human colorectal carcinoma and its correlation with tumor progression. *Anticancer Research*, 24, 675-681.



- KUNDU, J. K., NA, H. K., CHUN, K. S., KIM, Y. K., LEE, S. J., LEE, S. S., LEE, O. S., SIM, Y. C. & SURH, Y. J. 2003. Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells. *Journal of Nutrition*, 133, 3805s-3810s.
- KYLE, J. A., SHARP, L., LITTLE, J., DUTHIE, G. G. & MCNEILL, G. 2010. Dietary flavonoid intake and colorectal cancer: a case-control study. *Br J Nutr*, 103, 429-36.
- LADABAUM, U., CLARKE, C. A., PRESS, D. J., MANNALITHARA, A., MYER, P. A., CHENG, I. & GOMEZ, S. L. 2014. Colorectal Cancer Incidence in Asian Populations in California: Effect of Nativity and Neighborhood-Level Factors. *American Journal of Gastroenterology*.
- LE, N. H. & FODDE, R. 2008. Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. *British Journal of Cancer*, 98, 1886-1893.
- LEE, H., HERRMANN, A., DENG, J. H., KUJAWSKI, M., NIU, G. L., LI, Z. W., FORMAN, S., JOVE, R., PARDOLL, D. M. & YU, H. 2009. Persistently Activated Stat3 Maintains Constitutive NF-kappa B Activity in Tumors. *Cancer Cell*, 15, 283-293.
- LEE, K. M., HWANG, M. K., LEE, D. E., LEE, K. W. & LEE, H. J. 2010. Protective Effect of Quercetin against Arsenite-Induced COX-2 Expression by Targeting PI3K in Rat Liver Epithelial Cells. *Journal of Agricultural and Food Chemistry*, 58, 5815-5820.
- LI, B., VINCENT, A., CATES, J., BRANTLEY-SIEDERS, D. M., POLK, D. B. & YOUNG, P. P. 2009. Low Levels of Tumor Necrosis Factor alpha increase Tumor Growth by Inducing an Endothelial Phenotype of Monocytes Recruited to the Tumor Site. *Cancer Research*, 69, 338-348.
- LI, M., ZHANG, Z., HILL, D. L., WANG, H. & ZHANG, R. W. 2007. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. *Cancer Research*, 67, 1988-1996.
- LIANG, P. S., CHEN, T. Y. & GIOVANNUCCI, E. 2009. Cigarette smoking and colorectal cancer incidence and mortality: Systematic review and meta-analysis. *International Journal of Cancer*, 124, 2406-2415.
- LIAO, X. Y., MORIKAWA, T., LOCHHEAD, P., IMAMURA, Y., KUCHIBA, A., YAMAUCHI, M., NOSHO, K., QIAN, Z. R., NISHIHARA, R., MEYERHARDT, J. A., FUCHS, C. S. & OGINO, S. 2012. Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review. *Clinical Cancer Research*, 18, 2257-2268.
- LU, H. T., OUYANG, W. M. & HUANG, C. S. 2006. Inflammation, a key event in cancer development. *Molecular Cancer Research*, 4, 221-233.
- MANNA, S. K., MUKHOPADHYAY, A. & AGGARWAL, B. B. 2000. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. *Journal of Immunology*, 164, 6509-6519.
- MARTINEZ-FLOREZ, S., GUTIERREZ-FERNANDEZ, B., SANCHEZ-CAMPOS, S., GONZALEZ-GALLEGO, J. & TUNON, M. J. 2005. Quercetin attenuates nuclear factor-kappa B activation and nitric oxide production in interleukin-1 beta-activated rat hepatocytes. *Journal of Nutrition*, 135, 1359-1365.
- MARZOCHELLA, L., FANTINI, M., BENVENUTO, M., MASUELLI, L., TRESOLDI, I., MODESTI, A. & BEI, R. 2011. Dietary flavonoids: molecular mechanisms of action as anti-inflammatory agents. *Recent Pat Inflamm Allergy Drug Discov*, 5, 200-20.
- MASUDA, M., SUZUI, N. & WEINSTEIN, I. B. 2001. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. *Clinical Cancer Research*, 7, 4220-4229.
- MORRISON, V., HENDERSON, J., ZINOVIEFF, F., DAVIES, G., CARTMELL, R., HALL, A. & GOLLINS, S. 2012. Common, important, and unmet needs of cancer outpatients. *European Journal of Oncology Nursing*, 16, 115-123.

- MUTOH, M., TAKAHASHI, M., FUKUDA, K., MATSUSHIMA-HIBIYA, Y., MUTOH, H., SUGIMURA, T. & WAKABAYASHI, K. 2000. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. *Carcinogenesis*, 21, 959-963.
- NAUGLER, W. E. & KARIN, M. 2008. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. *Trends in Molecular Medicine*, 14, 109-119.
- NIKITEAS, N. I., TZANAKIS, N., GAZOULI, M., RALLIS, G., DANILIDIS, K., THEODOROPOULOS, G., KOSTAKIS, A. & PEROS, G. 2005. Serum IL-6, TNF alpha and CRP levels in Greek colorectal cancer patients: Prognostic implications. *World Journal of Gastroenterology*, 11, 1639-1643.
- NORAT, T., AUNE, D., CHAN, D. & ROMAGUERA, D. 2014. Fruits and Vegetables: Updating the Epidemiologic Evidence for the WCRF/AICR Lifestyle Recommendations for Cancer Prevention. *Advances in Nutrition and Cancer*, 159, 35-50.
- NORAT, T., BINGHAM, S., FERRARI, P., SLIMANI, N., JENAB, M., MAZUIR, M., OVERVAD, K., OLSEN, A., TJONNELAND, A., CLAVEL, F., BOUTRON-ROUULT, M. C., KESSE, E., BOEING, H., BERGMANN, M. M., NIETERS, A., LINSEISEN, J., TRICHOPOULOU, A., TRICHOPOULOS, D., TOUNTAS, Y., BERRINO, F., PALLI, D., PANICO, S., TUMINO, R., VINEIS, P., BUENO-DE-MESQUITA, H. B., PEETERS, P. H. M., ENGESET, D., LUND, E., SKEIE, G., ARDANAZ, E., GONZALEZ, C., NAVARRO, C., QUIROS, J. R., SANCHEZ, M. J., BERGLUND, G., MATTISSON, I., HALLMANS, G., PALMQVIST, R., DAY, N. E., KHAW, K. T., KEY, T. J., SAN JOAQUIN, M., HEMON, B., SARACCI, R., KAAKS, R. & RIBOLI, E. 2005. Meat, fish, and colorectal cancer risk: The European prospective investigation into cancer and nutrition. *Journal of the National Cancer Institute*, 97, 906-916.
- OZ, H. S., CHEN, T. S., MCCLAIN, C. J. & DE VILLIERS, W. J. S. 2005. Antioxidants as novel therapy in a murine model of colitis. *Journal of Nutritional Biochemistry*, 16, 297-304.
- PAGES, F., GALON, J., DIEU-NOSJEAN, M. C., TARTOUR, E., SAUTES-FRIDMAN, C. & FRIDMAN, W. H. 2010. Immune infiltration in human tumors: a prognostic factor that should not be ignored. *Oncogene*, 29, 1093-1102.
- PARK, J. H., CHOI, S. H. & CHUNG, J. W. 2013. The impact of early adequate antimicrobial therapy on 14-day mortality in patients with monomicrobial *Pseudomonas aeruginosa* and *Acinetobacter baumannii* bacteremia. *Journal of Infection and Chemotherapy*, 19, 843-849.
- PARK, J. H., MCMILLAN, D. C., HORGAN, P. G. & ROXBURGH, C. S. 2014. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. *Cancer Treat Rev*, 40, 68-77.
- PARK, J. K., HONG, R., KIM, K. J., LEE, T. B. & LIM, S. C. 2008. Significance of p-STAT3 expression in human colorectal adenocarcinoma. *Oncology Reports*, 20, 597-604.
- PARK, J. Y., MITROU, P. N., KEOGH, R. H., LUBEN, R. N., WAREHAM, N. J. & KHAW, K. T. 2012. Self-reported and measured anthropometric data and risk of colorectal cancer in the EPIC-Norfolk study. *International Journal of Obesity*, 36, 107-118.
- PATTERSON, R. E., NEUHOUSER, M. L., HEDDERSON, M. M., SCHWARTZ, S. M., STANDISH, L. J. & BOWEN, D. J. 2003. Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. *Journal of the American Dietetic Association*, 103, 323-328.
- PELLEGRINI, P., BERGHELLA, A. M., CONTASTA, I., DEL BEATO, T. & ADORNO, D. 2006. The study of a patient's immune system may prove to be a useful noninvasive tool for stage classification in colon cancer. *Cancer Biotherapy and Radiopharmaceuticals*, 21, 443-467.
- POPIVANOVA, B. K., KITAMURA, K., WU, Y., KONDO, T., KAGAYA, T., KANEKO, S., OSHIMA, M., FUJII, C. & MUKAIDA, N. 2008. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. *Journal of Clinical Investigation*, 118, 560-570.
- PRIZMENT, A. E., ANDERSON, K. E., VISVANATHAN, K. & FOLSOM, A. R. 2011. Association of Inflammatory Markers with Colorectal Cancer Incidence in the Atherosclerosis Risk in Communities Study. *Cancer Epidemiology Biomarkers & Prevention*, 20, 297-307.

- QU, H. Y., MADL, R. L., TAKEMOTO, D. J., BAYBUTT, R. C. & WANG, W. Q. 2005. Lignans are involved in the antitumor activity of wheat bran in colon cancer SW480 cells. *Journal of Nutrition*, 135, 598-602.
- REEDY, J., HAINES, P. S., STECKLER, A. & CAMPBELL, M. K. 2005. Qualitative comparison of dietary choices and dietary supplement use among older adults with and without a history of colorectal cancer. *Journal of Nutrition Education and Behavior*, 37, 252-258.
- ROSSI, M., NEGRI, E., TALAMINI, R., BOSETTI, C., PARPINEL, M., GNAGNARELLA, P., FRANCESCHI, S., DAL MASO, L., MONTELLA, M., GIACOSA, A. & LA VECCHIA, C. 2006. Flavonoids and colorectal cancer in Italy. *Cancer Epidemiol Biomarkers Prev*, 15, 1555-8.
- ROXBURGH, C. S. D. & MCMILLAN, D. C. 2012. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. *Cancer Treat Rev*, 38, 451-466.
- SAMUELS, Y., WANG, Z. H., BARDELLI, A., SILLIMAN, N., PTAK, J., SZABO, S., YAN, H., GAZDAR, A., POWELL, D. M., RIGGINS, G. J., WILLSON, J. K. V., MARKOWITZ, S., KINZLER, K. W., VOGELSTEIN, B. & VELCULESCU, V. E. 2004. High frequency of mutations of the PIK3CA gene in human cancers. *Science*, 304, 554-554.
- SARKAR, F. H. & LI, Y. W. 2008. NF-kappaB: a potential target for cancer chemoprevention and therapy. *Frontiers in Bioscience-Landmark*, 13, 2950-2959.
- SENOVILLA, L., VACCHELLI, E., GALON, J., ADJEMIAN, S., EGGERMONT, A., FRIDMAN, W. H., SAUTES-FRIDMAN, C., MA, Y. T., TARTOUR, E., ZITVOGEL, L., KROEMER, G. & GALLUZZI, L. 2012. Trial watch Prognostic and predictive value of the immune infiltrate in cancer. *Oncoimmunology*, 1, 1323-1343.
- SHEEHAN, K. M., SHEAHAN, K., O'DONOGHUE, D. P., MACSWEENEY, F., CONROY, R. M., FITZGERALD, D. J. & MURRAY, F. E. 1999. The relationship between cyclooxygenase-2 expression and colorectal cancer. *Jama-Journal of the American Medical Association*, 282, 1254-1257.
- SHISHODIA, S., SETHI, G. & AGGARWAL, B. B. 2005. Curcumin: Getting back to the roots. *Natural Products and Molecular Therapy*, 1056, 206-217.
- SIMONS, C. C. J. M., HUGHES, L. A. E., ARTS, I. C. W., GOLDBOHM, R. A., VAN DEN BRANDT, P. A. & WEIJENBERG, M. P. 2009. Dietary flavonol, flavone and catechin intake and risk of colorectal cancer in the Netherlands Cohort Study. *International Journal of Cancer*, 125, 2945-2952.
- SINGH, S. & AGGARWAL, B. B. 1995. Activation of Transcription Factor Nf-Kappa-B Is Suppressed by Curcumin (Diferuloylmethane) (Vol 270, Pg 24995, 1995). *Journal of Biological Chemistry*, 270, 30235-30235.
- SONG, Y. Q., MANSON, J. E., BURING, J. E., SESSO, H. D. & LIU, S. M. 2005. Associations of dietary flavonoids with risk of type 2 diabetes, and markers of insulin resistance and systemic inflammation in women: A prospective study and cross-sectional analysis. *Journal of the American College of Nutrition*, 24, 376-384.
- STEELE, R. J., MCCLEMENTS, P., WATLING, C., LIBBY, G., WELLER, D., BREWSTER, D. H., BLACK, R., CAREY, F. A. & FRASER, C. G. 2012. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. *Gut*, 61, 576-81.
- STEPTOE, A., GIBSON, E. L., VUONONVIRTA, R., HAMER, M., WARDLE, J., RYCROFT, J. A., MARTIN, J. F. & ERUSALIMSKY, J. D. 2007. The effects of chronic tea intake on platelet activation and inflammation: A double-blind placebo controlled trial. *Atherosclerosis*, 193, 277-282.
- STRYKER, S. J., WOLFF, B. G., CULP, C. E., LIBBE, S. D., ILSTRUP, D. M. & MACCARTY, R. L. 1987. Natural-History of Untreated Colonic Polyps. *Gastroenterology*, 93, 1009-1013.
- SUH, Y., AFAQ, F., JOHNSON, J. J. & MUKHTAR, H. 2009. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappa B-signaling pathways. *Carcinogenesis*, 30, 300-307.
- TAKETO, M. M. 1998. COX-2 and colon cancer. *Inflammation Research*, 47, S112-S116.

- TANAKA, K., OKIGAMI, M., TOIYAMA, Y., MORIMOTO, Y., MATSUSHITA, K., KAWAMURA, M., HASHIMOTO, K., SAIGUSA, S., OKUGAWA, Y., INOUE, Y., UCHIDA, K., ARAKI, T., MOHRI, Y., MIZOGUCHI, A. & KUSUNOKI, M. 2012. In vivo real-time imaging of chemotherapy response on the liver metastatic tumor microenvironment using multiphoton microscopy. *Oncology Reports*, 28, 1822-1830.
- TANG, L. Q., WEI, W. & WANG, X. Y. 2007. Effects and mechanisms of catechin for adjuvant arthritis in rats. *Advances in Therapy*, 24, 679-690.
- TANGREA, J. A., ALBERT, P. S., LANZA, E., WOODSON, K., CORLE, D., HASSON, M., BURT, R., CAAN, B., PASKETT, E., IBER, F., KIKENDALL, J. W., LANCE, P., SHIKE, M., WEISSFELD, J., SCHATZKIN, A. & GRP, P. P. S. 2003. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). *Cancer Causes & Control*, 14, 403-411.
- TERZIC, J., GRIVENNIKOV, S., KARIN, E. & KARIN, M. 2010. Inflammation and Colon Cancer. *Gastroenterology*, 138, 2101-U119.
- THEODORATOU, E., FARRINGTON, S. M., TENESA, A., MCNEILL, G., CETNARSKYJ, R., KORAKAKIS, E., DIN, F. V. N., PORTEOUS, M. E., DUNLOP, M. G. & CAMPBELL, H. 2014. Associations between dietary and lifestyle risk factors and colorectal cancer in the Scottish population. *European Journal of Cancer Prevention*, 23, 8-17.
- THEODORATOU, E., KYLE, J., CETNARSKYJ, R., FARRINGTON, S. M., TENESA, A., BARNETSON, R., PORTEOUS, M., DUNLOP, M. & CAMPBELL, H. 2007. Dietary flavonoids and the risk of colorectal cancer. *Cancer Epidemiology Biomarkers & Prevention*, 16, 684-693.
- TSUJII, M., KAWANO, S. & DUBOIS, R. N. 1997. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. *Proceedings of the National Academy of Sciences of the United States of America*, 94, 3336-3340.
- UDDIN, S., AHMED, M., HUSSAIN, A., ASSAD, L., AL-DAYE, F., BAVI, P., AL-KURAYA, K. S. & MUNKARAH, A. 2010. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. *International Journal of Cancer*, 126, 382-394.
- UMESALMA, S. & SUDHANDIRAN, G. 2010. Differential Inhibitory Effects of the Polyphenol Ellagic Acid on Inflammatory Mediators NF-kappa B, iNOS, COX-2, TNF-alpha, and IL-6 in 1,2-Dimethylhydrazine-Induced Rat Colon Carcinogenesis. *Basic & Clinical Pharmacology & Toxicology*, 107, 650-655.
- WANG, J. X., ZHANG, Q. Y., JIN, S., HE, D. N., ZHAO, S. & LIU, S. L. 2008. Genistein modulate immune responses in collagen-induced rheumatoid arthritis model. *Maturitas*, 59, 405-412.
- WANG, L. S., TU, Y. C., LIAN, T. W., HUNG, J. T., YEN, J. H. & WU, M. J. 2006. Distinctive antioxidant and antiinflammatory effects of flavonols. *Journal of Agricultural and Food Chemistry*, 54, 9798-9804.
- WARD, H. A., KUHNLE, G. G. C., MULLIGAN, A. A., LENTJES, M. A. H., LUBEN, R. N. & KHAW, K. T. 2010. Breast, colorectal, and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen intake derived from an improved database. *American Journal of Clinical Nutrition*, 91, 440-448.
- WCRF 2011. Colorectal Cancer 2011 Report. Food Nutrition, Physical Activity, and the Prevention of Colorectal Cancer. <http://www.wcrf.org/sites/default/files/Colorectal-Cancer-2011-Report.pdf>.
- WHITEHALL, V. L. J., RICKMAN, C., BOND, C. E., RAMSNES, I., GRECO, S. A., UMAPATHY, A., MCKEONE, D., FALEIRO, R. J., BUTTENSHAW, R. L., WORTHLEY, D. L., NAYLER, S., ZHAO, Z. Z., MONTGOMERY, G. W., MALLITT, K. A., JASS, J. R., MATSUBARA, N., NOTOHARA, K., ISHII, T. & LEGGETT, B. A. 2012. Oncogenic PIK3CA mutations in colorectal cancers and polyps. *International Journal of Cancer*, 131, 813-820.
- WOLIN, K. Y., YAN, Y., COLDITZ, G. A. & LEE, I. M. 2009. Physical activity and colon cancer prevention: a meta-analysis. *British Journal of Cancer*, 100, 611-616.

- WUNG, B. S., HSU, M. C., WU, C. C. & HSIEH, C. W. 2005. Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: Effects on the inhibition of STAT3 phosphorylation. *Life Sci*, 78, 389-397.
- YANG, F. J., OZ, H. S., BARVE, S., DE VILLIERS, W. J. S., MCCLAIN, C. J. & VARILEK, G. W. 2001. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. *Molecular Pharmacology*, 60, 528-533.
- YANG, G., SHU, X. O., LI, H. L., CHOW, W. H., CAI, H., ZHANG, X. L., GAO, Y. T. & ZHENG, W. 2009. Prospective cohort study of soy food intake and colorectal cancer risk in women. *American Journal of Clinical Nutrition*, 89, 577-583.
- YU, H., PARDOLL, D. & JOVE, R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. *Nature Reviews Cancer*, 9, 798-809.
- ZAMORA-ROS, R., NOT, C., GUINO, E., LUJAN-BARROSO, L., GARCIA, R. M., BIONDO, S., SALAZAR, R. & MORENO, V. 2013. Association between habitual dietary flavonoid and lignan intake and colorectal cancer in a Spanish case-control study (the Bellvitge Colorectal Cancer Study). *Cancer Causes & Control*, 24, 549-557.